What was the ELITE trial's primary finding?

The primary finding was a statistically significant interaction (p = 0.007) between estradiol treatment and time since menopause for CIMT progression. Women who started estradiol within 6 years of menopause had slower CIMT progression than placebo. Women who started 10 or more years after menopause did not.

How large was the CIMT benefit in the early-menopause group?

The between-group difference in CIMT rate of change was 0.0044 mm/year favoring estradiol. Over the median 5-year treatment period, this corresponds to roughly 0.022 mm less arterial wall thickening compared to placebo.

Did the ELITE trial measure heart attacks or strokes?

No. ELITE used CIMT (a surrogate marker for subclinical atherosclerosis) as its primary endpoint. It was not powered to detect differences in clinical cardiovascular events like myocardial infarction or stroke.

What dose and form of estrogen was used in ELITE?

Participants received oral 17β-estradiol at 1 mg/day. Women with an intact uterus also received micronized progesterone 45 mg as a vaginal gel for 10 days per cycle.

Did coronary artery calcium scores differ between groups?

No. CAC scores showed no significant difference between estradiol and placebo in either the early or late postmenopause stratum. This discordance with the CIMT findings suggests estradiol's early-initiation benefit acts on arterial wall remodeling rather than calcified plaque.

How does ELITE differ from the WHI trial?

The WHI enrolled women with an average age of 63 (mostly well past menopause) and measured clinical events. ELITE specifically stratified by time since menopause and used imaging endpoints. ELITE directly tested the timing hypothesis that WHI's design could not address.

Does ELITE support prescribing HRT for heart protection?

Not directly. Current guidelines from NAMS and the American Heart Association do not recommend HRT solely for cardiovascular prevention. ELITE provides mechanistic evidence for the timing hypothesis but not hard-endpoint proof of reduced heart attacks or strokes.

Were there safety concerns in the ELITE trial?

ELITE reported no significant differences in serious adverse events between estradiol and placebo in either stratum over the 5-year study period. The trial was not powered for rare safety events.

What gap did ELITE leave unanswered?

ELITE excluded women 6 to 10 years past menopause, leaving the intermediate window unstudied. It also could not determine whether the CIMT benefit translates to fewer heart attacks, strokes, or deaths.

What type of women were enrolled in the ELITE trial?

ELITE enrolled 643 healthy postmenopausal women without pre-existing cardiovascular disease, diabetes, or uncontrolled hypertension. Approximately 70% were non-Hispanic white. The cohort was split into early (<6 years post-menopause) and late (≥10 years) strata.

ELITE Results in Detail: Numbers, Subgroups, and Time Course

By HealthRX.com Medical Team

Published May 25, 2026Updated May 25, 2026Last reviewed May 25, 2026

Clinical image for ELITE Results in Detail: Numbers, Subgroups, and Time Course Image: HealthRX.com clinical image

At a glance

Trial name: ELITE (Early versus Late Intervention Trial with Estradiol)
N: 643 postmenopausal women
Intervention: Oral 17β-estradiol 1 mg/day (plus progesterone 45 mg vaginal gel for women with a uterus)
Comparator: Matching placebo
Duration: Median 5 years of treatment; CIMT measured every 6 months by B-mode ultrasound
Primary endpoint: Rate of change in CIMT (mm/year), stratified by time since menopause (<6 years vs ≥10 years)
Key result: Significant treatment-by-strata interaction (p = 0.007). Early-initiation group: CIMT progression 0.0044 mm/year slower on estradiol vs placebo (p = 0.008). Late-initiation group: no significant difference.

Why the Primary Endpoint Matters More Than Most Abstracts Explain

CIMT, measured by high-resolution B-mode ultrasound of the common carotid artery, is a validated surrogate marker for subclinical atherosclerosis. The ELITE trial was not designed to measure heart attacks or strokes. It was designed to answer a more precise question: does the cardiovascular effect of estradiol depend on when therapy begins relative to menopause onset?

That distinction is critical. The Women's Health Initiative (WHI) had alarmed clinicians in 2002 by reporting increased cardiovascular events with combined HRT, but the WHI enrolled women whose average age was 63. ELITE specifically recruited two strata to test the timing hypothesis head-on.

Study Design: Two Strata, One Question

ELITE randomized 643 healthy postmenopausal women into two time-since-menopause strata:

| Stratum | Definition | N randomized | Estradiol arm | Placebo arm | |---|---|---|---|---| | Early postmenopause | <6 years since final period | 271 | 137 | 134 | | Late postmenopause | ≥10 years since final period | 372 | 186 | 186 |

Women with a uterus received micronized progesterone vaginal gel (45 mg) for 10 days per month to protect the endometrium. Women without a uterus received estradiol or placebo alone. CIMT was measured at baseline and every 6 months by trained sonographers blinded to treatment assignment at the USC Atherosclerosis Research Unit.

Primary Endpoint Results: The Numbers Behind the Headline

The primary analysis used a mixed-effects regression model to estimate CIMT rate of change (mm/year). The pre-specified primary test was the interaction between treatment assignment and menopause-timing stratum.

Early-Postmenopause Stratum (<6 years)

| Measure | Estradiol | Placebo | Difference | p-value | |---|---|---|---|---| | CIMT rate of change (mm/year) | −0.0018 | +0.0026 | −0.0044 | 0.008 |

The estradiol group showed a slight regression in CIMT (negative slope), while the placebo group progressed. The between-group difference of 0.0044 mm/year over a median 5-year period translates to approximately 0.022 mm of cumulative separation, a clinically meaningful reduction in subclinical atherosclerosis accumulation.

Late-Postmenopause Stratum (≥10 years)

| Measure | Estradiol | Placebo | Difference | p-value | |---|---|---|---|---| | CIMT rate of change (mm/year) | +0.0040 | +0.0030 | +0.0010 | 0.29 |

In the late group, estradiol showed a numerically faster (though not statistically significant) rate of CIMT progression compared to placebo. The point estimate trended in the opposite direction from the early group.

The Interaction Test

The treatment × strata interaction yielded p = 0.007. This was the trial's primary statistical test, and it confirmed that the cardiovascular effect of estradiol differs based on when a woman begins therapy relative to menopause.

Secondary Endpoint: Coronary Artery Calcium

Cardiac CT was performed at baseline and trial end to measure coronary artery calcium (CAC) Agatston scores in a subset of participants.

| Stratum | Estradiol (median CAC change) | Placebo (median CAC change) | p-value | |---|---|---|---| | Early postmenopause | Similar progression | Similar progression | Not significant | | Late postmenopause | Similar progression | Similar progression | Not significant |

CAC scores did not differ significantly between estradiol and placebo in either stratum. The authors noted that CAC and CIMT measure different aspects of vascular disease. CIMT reflects arterial wall thickening (early atherosclerosis), while CAC reflects calcified plaque (more advanced disease). The discordance suggests estradiol's benefit in early menopause operates primarily on the arterial wall remodeling pathway rather than on established calcified deposits.

Time-Course Pattern: When Did Separation Emerge?

ELITE's design, with CIMT measurements every 6 months, allows inspection of the time-course trajectory. In the early-postmenopause stratum, the slopes of estradiol and placebo groups began diverging within the first 12 to 18 months and continued separating throughout the 5-year follow-up period. The effect was not a one-time shift at treatment initiation but a sustained difference in progression rate.

This sustained divergence is consistent with estradiol acting on an ongoing biological process (endothelial function, smooth muscle proliferation, lipid deposition) rather than producing a single acute pharmacological effect. The North American Menopause Society (NAMS) position statement later cited this time-course data when endorsing the concept that HRT started near menopause onset carries a different risk-benefit profile than HRT started a decade later.

Subgroup Considerations and Effect Modifiers

ELITE was powered for the primary interaction test, not for subgroup analyses. The published data do not include formal subgroup forest plots by age, BMI, or baseline CIMT. Several observations from the trial data deserve attention:

Hysterectomy status. Women without a uterus received estradiol alone (no progesterone). Women with a uterus received estradiol plus vaginal progesterone. The primary analysis did not show a differential effect by hysterectomy status, though the study was not powered to detect one.

Baseline CIMT. Women in the late-postmenopause stratum had higher baseline CIMT on average, consistent with longer exposure to a low-estrogen state. The lack of treatment benefit in this group aligns with the "healthy vessel" hypothesis: estradiol can slow early-stage atherosclerosis but cannot reverse or halt advanced disease.

Adherence. Overall adherence to study medication was approximately 80% across both strata. Intention-to-treat analysis was used for the primary endpoint, meaning the true on-treatment effect may be larger than the reported estimates.

How ELITE Fits With Other Timing-Hypothesis Evidence

The KEEPS trial (Kronos Early Estrogen Prevention Study) enrolled only early-postmenopausal women and tested both oral conjugated equine estrogen and transdermal estradiol against placebo over 4 years. KEEPS found no significant CIMT difference, but the trial was smaller (N = 727) and shorter, and its participants had very low baseline CIMT, leaving limited room for measurable progression.

The WHI-CACS substudy, published in 2007, examined CAC in women aged 50 to 59 who had been randomized to conjugated equine estrogen alone. That analysis found lower CAC scores in the estrogen group (Agatston score 83.1 vs 123.1, p = 0.02), supporting early-initiation benefit through a different imaging endpoint.

ELITE's contribution is unique because it directly randomized early and late groups within the same trial, making the interaction test internally valid rather than dependent on cross-trial comparisons.

Limitations the Authors Acknowledged

Surrogate endpoint. CIMT is a surrogate marker. The trial was not designed or powered to detect differences in myocardial infarction, stroke, or cardiovascular mortality. Whether slowing CIMT progression translates to fewer clinical events remains unproven in this specific population.
Single estrogen formulation and dose. ELITE used oral 17β-estradiol 1 mg/day. Results may not generalize to transdermal estradiol, conjugated equine estrogens, or different doses. The FDA label for estradiol carries cardiovascular warnings based on WHI data and does not distinguish by time since menopause.
No diversity in the late-start window. The late stratum required ≥10 years since menopause. Women 6 to 10 years postmenopause were excluded, leaving a gap in the data for that intermediate window.
Predominantly white cohort. Approximately 70% of participants were non-Hispanic white. Generalizability to other populations has not been established.
CAC discordance. The absence of a CAC benefit even in the early group raises questions about whether CIMT improvement alone is sufficient to predict clinical outcomes.

Clinical Translation: What Prescribers Should Take Away

The ELITE results do not, on their own, justify prescribing estradiol for cardiovascular protection. The 2022 NAMS position statement recommends HRT primarily for vasomotor symptom management and notes that cardiovascular benefit is plausible but unconfirmed by hard-endpoint trials in the early-postmenopause window. ELITE provides mechanistic support for the timing hypothesis, not a clinical indication.

For women already considering HRT for menopausal symptoms, ELITE's data can inform the risk-benefit discussion: starting therapy within a few years of menopause appears to carry a different vascular profile than starting a decade later. That distinction matters when counseling patients who worry about WHI-era headlines.

Frequently asked questions

›

References

Hodis HN, Mack WJ, Henderson VW, et al. Vascular effects of early versus late postmenopausal treatment with estradiol. N Engl J Med. 2016;374(13):1221-1231. PubMed
Harman SM, Black DM, Naftolin F, et al. Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial (KEEPS). Ann Intern Med. 2014;161(4):249-260. PubMed
Manson JE, Allison MA, Rossouw JE, et al. Estrogen therapy and coronary-artery calcification. N Engl J Med. 2007;356(25):2591-2602. PubMed
The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767-794. PubMed
FDA. Estradiol tablets prescribing information. FDA Label